IL2 and neoplasm: Moreover, 5797 patients received systemic chemotherapy, 122 received the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab, 14 received immunotherapy with tumor-infiltrating lymphocytes (TILs) and interleukin (IL)-2, 1478 underwent HAI of chemotherapy and 1204 underwent only surgical management without adjuvant treatment.